When ankle cartilage damage needs more than rest

For many patients with ankle pain that has not settled after months of physiotherapy, the question eventually becomes a practical one: is there a way to treat this without an operation?

The answer depends on what kind of damage is present. Osteochondral lesions of the talus — OLT for short — are localised injuries to the cartilage surface and the bone immediately beneath it on the ankle's primary weight-bearing structure. They develop most commonly after a sprain or repeated impact, producing a recognisable pattern of deep ankle pain, intermittent swelling, and a sense of instability that does not fully resolve with rest. Ankle osteoarthritis from OLT tends to affect younger, active individuals and is predominantly post-traumatic in origin.

Conservative management — physiotherapy, load modification, bracing, and activity restriction — is a reasonable first step and achieves satisfactory results in roughly half of acute, non-displaced OLT cases. For the remaining patients, that figure carries weight: it confirms that seeking active intervention is clinically justified, not impatience.

The choice of intervention matters as much as the decision to act. Arthroscopic surgery has long been the standard next step, but not every patient is ready for theatre, anaesthesia, and the recovery that follows. For those with a focal, localised defect who have worked through conservative care, a non-surgical, ultrasound-guided injectable scaffold sits in a distinct middle ground — neither passive management nor an operative procedure.

Diffuse ankle osteoarthritis sits outside that frame. Where cartilage loss is widespread rather than focal, the clinical conversation shifts appropriately towards joint preservation or replacement rather than a scaffold approach.

How ChondroFiller injection works in a cartilage defect

ChondroFiller Liquid is a collagen type I hydrogel — the same structural protein that forms the backbone of healthy cartilage tissue. Critically, it contains no donor cells and no biological material from another person: it is an acellular scaffold, CE-marked since 2013, with over 20,000 implantations across more than a decade of clinical use.

Once injected into the defect, the liquid gels in situ, conforming to the shape of the lesion. What happens next is the key distinction. The scaffold does not replace cartilage directly. Instead, it creates a structured biological matrix — a framework of collagen fibres with the appropriate architecture to signal the body that repair is needed at that site. The patient's own progenitor and repair cells migrate into the scaffold, populate it, and begin remodelling it towards cartilage-like tissue. This process is called matrix-induced chondrogenesis.

The cellular ingress is not theoretical. A 2025 ex vivo osteochondral study measured a 2.4-fold increase in DNA content at the scaffold site by day 14, confirming that repair cells actively enter the matrix rather than simply accumulating around it.

Hyaluronic acid injections work differently and serve a different purpose: they reduce friction and provide short-term symptomatic relief, but the fluid is absorbed within weeks and leaves no structural template behind. Synthetic non-integrable gels similarly offer no surface for cell attachment or remodelling. ChondroFiller's biological origin is what makes integration possible.

In practical patient-selection terms, the scaffold can address defects up to 3 cm² in area, extendable to 6 cm² where clinical assessment supports it — a range that covers the majority of focal osteochondral lesions encountered in the ankle.

What happens during the procedure

The appointment itself involves no operating theatre, no general anaesthetic, and no surgical incision. The ChondroFiller injection for an ankle cartilage lesion is delivered as a single outpatient procedure, typically lasting 30 to 45 minutes, after which patients leave the same day.

Under real-time ultrasound, the clinician watches the needle on a live image as it is directed to the lesion site on the talus. This image-guided placement allows the collagen scaffold to be deposited precisely within the defect — a technically meaningful step, because accurate filling determines how well the material integrates with the surrounding tissue. At London Cartilage Clinic on Harley Street, Professor Paul Lee leads this work; the clinic is the first in the UK to offer ChondroFiller as a non-surgical injection for ankle cartilage damage.

IV antibiotic cover is given as a standard precaution during the procedure. Because the scaffold's initial mechanical stability is limited immediately after application, a period of reduced loading on the ankle is advisable before returning to full weight-bearing — the specifics of which are discussed at a six-week follow-up included as part of the treatment package.

That package is self-funded, and the pricing is straightforward: treatment starts at £3,000 for a single box of scaffold (2.3 mL), rising to £5,500 for two boxes and £8,000 for three. The fee covers consultation, ultrasound, the ChondroFiller product, the injection itself, and the six-week review. Most patients with a focal ankle lesion are treated with one box.

What the clinical evidence currently shows

No clinical trial has yet reported ChondroFiller injection outcomes specifically in the talus. That absence matters, and patients considering treatment should know it before anything else.

What exists is a consistent body of cross-joint evidence — and the distinction between the two deserves some unpacking.

In a prospective hip cohort of 26 patients followed for between 12 and 60 months, 17 of 21 evaluable patients achieved good or excellent results on MRI-confirmed cartilage healing. Notably, patients with pre-existing osteoarthritis (Tönnis grade 2–3) fared poorly, reinforcing that ChondroFiller injection is a focal-defect treatment rather than a remedy for diffuse joint degeneration. A knee RCT comparing ChondroFiller with microfracture reported significant IKDC score improvement at 3, 6, and 12 months (p<0.05), with MRI demonstrating good immediate defect filling and progressive cartilage maturation over time; no adverse events were recorded in the ChondroFiller group.

The most structurally relevant data for ankle patients comes from a 2025 wrist study (n=59, ChondroFiller subgroup n=25). At follow-up arthroscopy, ChondroFiller-treated patients showed significantly better cartilage quality than controls — median Outerbridge grade 1.5 versus 3.0 (p=0.006) and ICRS grade 1 versus 3 (p=0.002). The wrist is anatomically instructive here: it is a small joint with articular surfaces and biomechanical load patterns that more closely resemble the ankle than either the knee or hip do. The study also found that fibrous tissue formed only when defects were overfilled; flush application was free of it — a technical observation with direct relevance to precise, ultrasound-guided placement.

For context against the existing surgical landscape, combined arthroscopic microfracture plus MSC injection in OLT patients achieves an AOFAS score of approximately 81.5 and a MOCART score of approximately 74.3 at around three years — figures drawn from a 2024 meta-analysis of 348 patients. These figures represent the current best surgical benchmark for biologically augmented repair in the talus, and they provide a useful reference point against which future ankle-specific ChondroFiller data can be measured.

Across all joints and more than 20,000 implantations, the product's complaint rate sits at approximately 0.06% — a safety signal that is meaningful even in the absence of ankle-specific trials.

Recovery and weight-bearing after the injection

Injecting a collagen scaffold into a joint defect is a different proposition from injecting a lubricant or a pain-relief agent. The material has to gel, stabilise, and integrate with surrounding tissue before it can tolerate load — and in the ankle, load is constant. The talus carries the full weight of the body with every step, making the post-injection period clinically significant in a way it is not for joints such as the wrist or elbow.

A biomechanical study found that ChondroFiller could not protect opposing cartilage under cyclic loading in the immediate post-application phase, attributing this directly to the material's initial mechanical instability. Protected weight-bearing after the procedure is therefore not an arbitrary precaution — it reflects what the laboratory data shows about scaffold behaviour before integration is established.

The first six weeks are treated as a structured loading phase. The follow-up review at that point — included in the treatment package — is where progression is formally assessed and a return-to-activity plan agreed. Crutches or modified footwear may be needed in the early part of this period depending on the size and location of the lesion and individual response. Compared with post-surgical rehabilitation, this is substantially less demanding: there is no theatre wound to heal, no arthroscopic recovery, and — unlike ACI or MACI — no second procedure and no cell-culture waiting period to navigate. The ChondroFiller injection is single-stage from the outset, with no harvest site and no laboratory interval.

Patients should approach the recovery as a graduated process rather than a binary event. Full return to walking and, eventually, to exercise is the expected trajectory; the pace of that progression is guided by clinical review rather than fixed in advance.

Is ChondroFiller injection the right next step for your ankle?

Three factors tend to determine whether ChondroFiller injection is the appropriate next step: the nature of the damage, the treatment history, and what the patient is trying to achieve.

The procedure is suited to patients with a focal osteochondral lesion of the talus who have not responded adequately to conservative management and who want to avoid or defer arthroscopic surgery. Age is not an absolute barrier. What matters more is lesion character: the hip cohort at 3–5 years found that patients with established osteoarthritis at Tönnis grade 2–3 did poorly — confirming that the scaffold addresses focal defects, not the background of a joint that has already deteriorated more broadly.

For patients with more complex presentations — where synovial involvement is significant or cartilage loss has progressed further — ChondroFiller injection can be used alongside Arthrosamid, a polyacrylamide hydrogel that acts on the synovial lining rather than the cartilage defect itself. The two work differently: ChondroFiller is the regenerative scaffold element; Arthrosamid provides synovial cushioning. Autologous mesenchymal stem cells, drawn from bone marrow or adipose tissue, may be added as a third component in end-stage presentations. Each element is individually evidenced, but the combined protocol as a whole has not yet been tested in a randomised controlled trial.

Assessments are carried out at the London Cartilage Clinic on Harley Street, where clinical findings and imaging are reviewed together before any treatment plan is agreed. Professor Paul Lee leads the service. For patients who have moved through conservative care without resolution, the value of a structured clinical assessment is precisely that it converts an open question — is this the right treatment for this lesion? — into a clear, evidence-based answer.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Implantation of ChondroFiller Liquid as a scaffold for chondral lesions of the knee joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
3. [3] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
4. [4] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
5. [5] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
6. [6] Arthroscopic microfracture and MSC injection vs isolated microfracture for OLT: meta-analysis. (2024). https://doi.org/10.1053/j.jfas.2024.08.011 https://doi.org/10.1053/j.jfas.2024.08.011
7. [7] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z